– Study met all primary endpoints, including 79.2% sensitivity for colorectal cancer (CRC) and 91.5% specificity for non-advanced colorectal neoplasia – – PREEMPT CRC, the largest study of a ...
The MarketWatch News Department was not involved in the creation of this content. -- PREEMPT CRC, the largest prospective study of its kind, met all primary efficacy endpoints and surpassed CMS ...
– As presented later this week at the ASCO GI conference, the large case-control validation study of nearly 1,000 samples highlights a head-to-head comparison with the test's first version, which is ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
SOUTH SAN FRANCISCO, Calif., March 6, 2023 /PRNewswire/ -- Today Freenome, a privately held biotech company, presents a subject population analysis from PREEMPT CRC, a study for the detection of ...
The MarketWatch News Department was not involved in the creation of this content. -- Deal worth up to $885 million based on achievement of certain regulatory and screening guideline milestones -- -- ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
BRISBANE, Calif., June 2, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the publication of detailed results from the pivotal ...
BRISBANE, Calif., June 2, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the publication of detailed results from the pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results